Compare MGNI & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MGNI | MNKD |
|---|---|---|
| Founded | 2007 | 1991 |
| Country | United States | United States |
| Employees | 514 | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | 2014 | 2004 |
| Metric | MGNI | MNKD |
|---|---|---|
| Price | $12.11 | $2.62 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 7 |
| Target Price | ★ $25.22 | $8.64 |
| AVG Volume (30 Days) | 1.7M | ★ 4.9M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 493.75 | N/A |
| EPS | ★ 0.95 | 0.02 |
| Revenue | $156,414,000.00 | ★ $348,966,000.00 |
| Revenue This Year | $6.33 | $35.81 |
| Revenue Next Year | $9.73 | $11.89 |
| P/E Ratio | ★ $12.67 | $128.25 |
| Revenue Growth | ★ 25.45 | 22.23 |
| 52 Week Low | $9.29 | $2.23 |
| 52 Week High | $26.65 | $6.51 |
| Indicator | MGNI | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 46.47 | 37.57 |
| Support Level | $11.81 | $2.52 |
| Resistance Level | $14.48 | $6.18 |
| Average True Range (ATR) | 0.51 | 0.14 |
| MACD | 0.04 | 0.12 |
| Stochastic Oscillator | 45.24 | 85.56 |
Magnite is a supply-side advertising platform that provides technology and yield management solutions to content publishers, enabling them to monetize their digital advertising inventory. Magnite receives a percentage of all advertising inventory that it sells. 43% of Magnite's revenue is derived from connected television, or CTV, streaming platforms, 40% from mobile applications, and the remainder from general websites. Beyond the typical monetization responsibilities inherent to an SSP, Magnite also provides upstream advertising servers to CTV publishers, allowing them to have granular control over direct-sold, programmatic guaranteed, and open-auction logic. Magnite competes with other independent SSPs, supply path optimization solutions, and closed ecosystems like Meta.
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.